There is a reliable pattern in hemp-derived products. A restriction lands on one cannabinoid, the industry moves to another, and the cycle repeats. Delta-9 gets limited, delta-8 appears. Delta-8 gets restricted in a state, and something else takes the shelf.
Section 781 of Public Law 119-37 was drafted by people who had watched that happen several times. It closes the route in three separate places, and understanding all three matters if you are planning a reformulation.
Clause one: the cap is combined, not THC-only
Final hemp-derived cannabinoid products are excluded from the hemp definition if they contain:
“greater than 0.4 milligrams combined total per container of… total tetrahydrocannabinols (including tetrahydrocannabinolic acid); and any other cannabinoids that have similar effects (or are marketed to have similar effects) on humans or animals as a tetrahydrocannabinol (as determined by the Secretary of Health and Human Services).”
Two things to notice. It is a combined total, so a second intoxicating cannabinoid adds to the same budget rather than opening a new one. And it captures cannabinoids “marketed to have similar effects”, which means the marketing itself is evidence. A product sold on the promise of a similar experience is describing itself into the clause.
Clause two: not naturally producible
Separately, products are excluded if they contain “cannabinoids that are not capable of being naturally produced by a Cannabis sativa L. plant”.
That covers the genuinely novel synthetics, the compounds that do not occur in the plant at all and were designed to sit outside whatever definition existed at the time.
Clause three: made outside the plant
This is the one that does the most work and gets the least attention. Products are excluded if they contain cannabinoids that:
“are capable of being naturally produced by a Cannabis sativa L. plant; and were synthesized or manufactured outside the plant”
Read that against how the alternative cannabinoid market actually operates. Most of these compounds occur in the plant only in trace amounts, far too little to extract economically, so they are produced by converting CBD in a reactor.
The clause does not care about the quantity. It objects to the manufacturing route. A product could sit comfortably under the milligram cap and still fall outside the definition because of how the molecule was made.
What that leaves
Genuinely low-dose products under the combined cap, made from cannabinoids the plant actually produced.
Non-cannabinoid hemp, which the statute protects explicitly through its separate industrial hemp definition covering stalk, fiber, grain, seed, oil, cake, nut, hull and other non-cannabinoid preparations.
And products whose value is not cannabinoid-derived at all. Terpenes are not cannabinoids and do not produce tetrahydrocannabinol-like effects, so none of these three clauses reach them. That is the structural reason the category’s centre of gravity moves toward aroma-led and flavor-led formulation rather than toward the next molecule.
The strategic read
If your product plan for November involves finding a cannabinoid that is not covered, read the three clauses again and check it against all of them rather than against the cap alone. Most substitution plans clear one and fail another.
The more durable question is what your customers were buying. If a meaningful share were buying flavour, aroma and ritual, that demand survives every one of these clauses. If they were buying intoxication, the honest answer is that this statute is aimed precisely at you, and the state-licensed cannabis market is where that product legally lives.
About this article
Written 27 July 2026 and checked against the statute, the Federal Register and the published papers rather than against secondary coverage. Regulatory positions in this area are moving, so check the date before relying on it. Nothing here is legal, tax or medical advice.
